Close Menu

NEW YORK – Investment bank Cowen on Thursday initiated coverage of DermTech with a rating of Outperform and price target of $20.

In a note, analyst Ryan Blicker lauded the company's noninvasive test for early melanoma detection, PLA, which uses a proprietary adhesive patch sampling technology to measure aberrant gene expression in suspect skin lesions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.